UNSPSC 51241526: Fluorescein/proparacaine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.

UNSPSC 51241526 Fluorescein/proparacaine, a Commodity code, encompasses ophthalmic diagnostic and topical anesthetic pharmaceutical products that state and local government health systems, clinics, and public health facilities procure for eye examinations and minor ocular procedures. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and participating state and local agencies source these products through established pharmaceutical distribution channels, typically bundled within broader generic and over-the-counter pharmaceutical procurement vehicles rather than as stand-alone line items. State and local buyers include health departments, regional clinics, public university medical facilities, and multi-state cooperative purchasing organizations that aggregate demand across member jurisdictions to negotiate volume pricing and standardized supply agreements.

MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026 with a response due date of March 26, 2026 to establish multiple pharmaceutical supplier contracts covering generic multi-source products and OTC items for distribution across participating state and local facilities in Minnesota, Oregon, and other MMCAP member jurisdictions. Vendors must supply products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), maintain cGMP and DSCSA compliance, carry specified insurance including $5 million commercial general liability coverage, and accept a 3 percent administrative fee on all purchases. The contract term is two years for new vendors with optional extensions, and MMCAP reserves sole discretion to make single, dual, or multi-awards based on therapeutic considerations and member needs. Evaluation weighs price competitiveness most heavily at 75 percent, with administrative compliance, EDI capability, and fixed pricing accounting for the remainder.